Investing.com -- Barclays downgraded Illumina Inc (NASDAQ:ILMN) to "Underweight" given growing uncertainty in China, rising competition from Roche in the clinical market, and weaker-than-expected ...

Analysts' ratings for Illumina ILMN over the last quarter vary from bullish to bearish, as provided by 11 analysts. The table below provides a concise overview of recent ratings by analysts ...

Barclays analysts following the closing arguments came away with mixed views. “We listened to the entire day of closing arguments and there were certainly times where we felt a lot worse than we ...

Barclays has responded to a customer’s concern regarding a change in the interest rate on their savings account. The customer contacted the bank on social media as their rate had dropped, to ask ...

On Monday, Piper Sandler confirmed its Overweight rating on Illumina shares (NASDAQ: ILMN), maintaining a $185.00 price target.The research firm’s analyst highlighted a challenging near-term outlook ...

Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies ...

What a brutal six months it’s been for Illumina. The stock has dropped 33.6% and now trades at $89.03, rattling many shareholders. This may have investors wondering how to approach the situation.

Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study ...

Barclays has escalated its efforts to protect its customers by issuing a stark warning on June 5, highlighting the ongoing financial scams which have been stealing money from some account holders.